Royal Bank of Canada Purchases 4,493 Shares of LivaNova PLC (NASDAQ:LIVN)

Royal Bank of Canada raised its position in LivaNova PLC (NASDAQ:LIVN) by 13.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 37,732 shares of the company’s stock after buying an additional 4,493 shares during the period. Royal Bank of Canada’s holdings in LivaNova were worth $2,715,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of LIVN. Nisa Investment Advisors LLC raised its position in LivaNova by 8.9% in the second quarter. Nisa Investment Advisors LLC now owns 1,900 shares of the company’s stock valued at $137,000 after purchasing an additional 155 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in LivaNova by 1.4% during the second quarter. Oregon Public Employees Retirement Fund now owns 19,726 shares of the company’s stock worth $1,419,000 after purchasing an additional 278 shares during the period. Oakbrook Investments LLC acquired a new stake in LivaNova during the second quarter worth approximately $245,000. Daiwa Securities Group Inc. grew its stake in LivaNova by 29.5% during the second quarter. Daiwa Securities Group Inc. now owns 19,665 shares of the company’s stock worth $1,415,000 after purchasing an additional 4,475 shares during the period. Finally, Strs Ohio grew its stake in LivaNova by 7.0% during the second quarter. Strs Ohio now owns 20,000 shares of the company’s stock worth $1,439,000 after purchasing an additional 1,300 shares during the period. Hedge funds and other institutional investors own 88.36% of the company’s stock.

NASDAQ LIVN opened at $73.12 on Wednesday. The business has a 50 day simple moving average of $76.34 and a 200 day simple moving average of $74.92. LivaNova PLC has a one year low of $64.80 and a one year high of $126.99. The stock has a market capitalization of $3.43 billion, a P/E ratio of 23.07, a P/E/G ratio of 2.78 and a beta of 0.54. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.95 and a quick ratio of 0.67.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, missing the consensus estimate of $0.59 by ($0.03). LivaNova had a positive return on equity of 8.56% and a negative net margin of 23.86%. The business had revenue of $277.20 million for the quarter, compared to analyst estimates of $275.14 million. During the same period in the prior year, the business earned $0.96 EPS. The company’s revenue for the quarter was down 3.6% on a year-over-year basis. Equities analysts expect that LivaNova PLC will post 2.79 earnings per share for the current year.

In other LivaNova news, CEO Damien Mcdonald sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $77.53, for a total value of $77,530.00. Following the completion of the sale, the chief executive officer now owns 61,774 shares of the company’s stock, valued at $4,789,338.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Daniel Jeffrey Moore sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $84.56, for a total value of $126,840.00. Insiders sold 14,000 shares of company stock valued at $1,118,545 in the last three months. Insiders own 0.41% of the company’s stock.

Several equities research analysts recently commented on LIVN shares. BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research note on Wednesday, July 31st. ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research cut LivaNova from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $91.00 target price on shares of LivaNova in a research note on Friday, September 6th. Finally, BidaskClub cut LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 24th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $98.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV”) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.

See Also: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.